Form 4: Pfizer Executive Mikael Dolsten Reports Stock Transaction

Mikael Dolsten, President of R&D at Pfizer, reports the withholding of shares to cover tax obligations upon settlement of stock units.

Summary

• On February 23, 2024, Mikael Dolsten, President of R&D at Pfizer, reported a transaction involving Pfizer's common stock.
• The transaction involved the withholding of 24,822 shares to satisfy tax obligations related to the settlement of stock units from previously exercised stock appreciation rights.
• The price per share for the transaction was $27.76.
• Following the transaction, Dolsten directly owns 343,166 shares of Pfizer common stock.
• Dolsten also indirectly owns 1,981 shares through a Rule 16b-3 Plan.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a routine stock transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

This is a routine filing related to executive compensation and stock ownership, common in publicly traded companies like Pfizer. It provides transparency into the transactions of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for executives at publicly traded companies like Pfizer, mirroring similar disclosures from peers such as Johnson & Johnson, Merck, and AbbVie.
• The reporting requirements are consistent across the pharmaceutical industry, ensuring transparency in insider trading activities.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it is related to tax obligations of an executive.
• It provides transparency to shareholders regarding executive stock ownership.

Key Dates